"Enhancer of Zeste Homolog 2 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A histone-lysine N-methyltransferase and catalytic subunit of Polycomb Repressive Complex 2. It methylates LYSINE 9 (H3K9me) and LYSINE 27 (H3K27me) of HISTONE H3, leading to transcriptional repression of the affected target gene. EZH2 also methylates non-histone proteins such as GATA4 TRANSCRIPTION FACTOR and the nuclear receptor RORA. It regulates CIRCADIAN CLOCKS via histone methylation at the PROMOTER REGIONS of the circadian genes and its repressive activity is also important for the identity and differentiation of EMBRYONIC STEM CELLS.
Descriptor ID |
D000071221
|
MeSH Number(s) |
D05.500.781.750.250 D08.811.913.555.500.800.400.500.500 D12.776.660.235.600.200.250 D12.776.664.235.800.200.250 D12.776.930.780.890.200.250
|
Concept/Terms |
Enhancer of Zeste Homolog 2 Protein- Enhancer of Zeste Homolog 2 Protein
- Lysine N-Methyltransferase-6
- Lysine N Methyltransferase 6
- Histone-Lysine N-Methyltransferase EZH2
- EZH2, Histone-Lysine N-Methyltransferase
- Histone Lysine N Methyltransferase EZH2
- Enhancer of Zeste Homolog 2
|
Below are MeSH descriptors whose meaning is more general than "Enhancer of Zeste Homolog 2 Protein".
Below are MeSH descriptors whose meaning is more specific than "Enhancer of Zeste Homolog 2 Protein".
This graph shows the total number of publications written about "Enhancer of Zeste Homolog 2 Protein" by people in this website by year, and whether "Enhancer of Zeste Homolog 2 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2009 | 0 | 1 | 1 |
2012 | 0 | 1 | 1 |
2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Enhancer of Zeste Homolog 2 Protein" by people in Profiles.
-
EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. Mol Cancer Res. 2020 02; 18(2):278-286.
-
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov. 2012 Nov; 2(11):1024-35.
-
Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2. Cell Cycle. 2009 Jul 01; 8(13):1991-6.